Sylvant Approval History
- FDA approved: Yes (First approved April 22nd, 2014)
- Brand name: Sylvant
- Generic name: siltuximab
- Company: Janssen Pharmaceuticals, Inc.
- Treatment for: Multicentric Castleman's Disease
Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease.
Development History and FDA Approval Process for Sylvant
|Apr 23, 2014||FDA Approves Sylvant for Multicentric Castleman’s Disease|
|Sep 3, 2013||Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.